Find Clinical Trials & Studies
ELEVATE PD
I'm Interested!
Open-Label Phase 4 Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease Patients
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase IV
- Conditions Being Studied: Parkinsons Disease
Study Purpose
The main purpose of this study to see how effective and safe CREXONT is for people with Parkinson’s disease (PD) in everyday life. CREXONT is a mix of levodopa (LD) and carbidopa (CD), used to treat PD. LD crosses into the brain and turns into dopamine, helping relieve PD symptoms. While CD doesn’t enter the brain, it prevents the conversion of LD to dopamine outside the brain and helps in providing more LD to brain to be converted to dopamine thus extending the effects of LD.
- UH IRB: STUDY20250190
- StudyID: 2024-01631
- ClinicalTrials.gov: N/A
I'm Interested!
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422